Skip to content
Buy This GLP
← Research
Evidence

GLP-1 Lean Mass Loss Against Control: 0.78 kg in a Three-Trial Meta-Analysis

Compared with control groups, lean mass fell 0.78 kg more and fat mass 3.43 kg more. Those are differences from a comparator, which is why larger absolute figures also hold.

Editorial profile: Carla MedinaBuy This GLP Editorial Team6 min read
Extra loss compared with controlfat mass−3.43 kglean mass−0.78 kgBoth are differences against a control group, not totals.Lean mass includes nonmuscular tissue.Three trials, 171 participants.

In studies that measure lean mass from baseline, the number describes the total change within a group. In the three-trial analysis below, 0.78 kg describes the difference in change between the treatment and comparison groups.

What this analysis did

A search of five databases to the end of 2024 turned up 2,776 articles, of which three randomized trials covering 171 participants met the criteria: adults with obesity, without type 2 diabetes, on a GLP-1, with body composition reported. [1] On average, treatment groups lost 0.78 kg more lean mass and 3.43 kg more fat mass than comparison groups. The paper gives a slightly different lower confidence limit for lean mass in the abstract and results section. Heterogeneity was substantial for both outcomes, with I² of 63.2% for lean mass and 78.2% for fat mass.

What the split looks like

Taking the two point estimates at face value, the extra weight lost on the drug was about 18.5% lean and the rest fat. That division is our arithmetic rather than the paper’s — it uses only the central estimates, ignores both confidence intervals, and ignores the substantial heterogeneity. Treat it as a shape, not a measurement.

Our summary of lean mass as a share of total weight lost covers studies with different comparison groups and follow-up periods. The roughly one-third share discussed there cannot be compared directly with a ratio of two treatment-versus-control estimates.

Why the evidence base is this small

Three trials met the eligibility criteria, which required randomization, body-composition measurements and participants without type 2 diabetes. With so few studies and substantial differences between estimates, the pooled numbers may change as more trials become available.

What the findings can tell you

The authors discuss physical activity and nutrition alongside treatment. Our review of lean mass and resistance exercise covers a separate trial designed to test exercise during tirzepatide treatment. The three-trial meta-analysis did not establish a training plan or protein target.

Frequently asked

Is the lean-mass loss 0.78 kg or six kilograms?
The 0.78 kg estimate compares changes between groups across three trials. Larger figures from other studies can describe the total change within a treatment group.
How much of the extra loss was fat?
Fat mass fell 3.43 kg more than control against 0.78 kg of lean. Dividing those point estimates gives roughly four-fifths fat, which is this site's arithmetic and ignores the confidence intervals.
Why only three trials?
The authors required randomized trials with body-composition measurements in adults without type 2 diabetes. Three trials met their criteria.
Does this change what to do about it?
The authors discuss adding physical activity and nutritional support. This analysis did not test a specific training plan or protein target.

Sources

  1. [1] Woźniak M, et al. (2026). The Impact of Glucagon-like Peptide-1 (GLP-1) Receptor Agonists on Body Composition in Individuals with Overweight and Obesity: A Systematic Review and Meta-Analysis Journal of Clinical Medicine. PMID 42739822

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence